---
title: "Pinealon Memory Benefits, Study Dosage, Side Effects, FDA Status"
description: "Pinealon/EDR guide: cognitive benefits from studies, dosage from studies, side effects, FDA status, legal status, and brain research limits."
canonical_url: "https://khavinsonatlas.com/peptides/pinealon.html"
last_updated: "2026-05-05"
---

# Pinealon / EDR

Pinealon is a synthetic tripeptide usually written EDR, or Glu-Asp-Arg. It is searched around memory, cognition, nootropic claims, brain aging, circadian biology, dosage, side effects, FDA status, and legal status.

## Evidence map

Pinealon literature is mostly mechanism-focused or secondary regional literature. It should not be presented as proof of nootropic benefit, disease treatment, or consumer-use protocols.

## Benefits and study-only dosage

The strongest identity fact is the EDR sequence and the brain/nervous-system context in Khavinson taxonomy. Any study dose or exposure should be treated as study context only, not a consumer Pinealon dosage.

## Side effects

Reliable adverse-event rates, contraindications, interactions, and route-specific risks are not established for consumer Pinealon products. Side effects cannot be inferred from the EDR sequence alone.

## FDA and legal status

This site does not identify an FDA-approved Pinealon drug in the United States as of the May 5, 2026 review. Vendor pages, supplement labels, research-use labels, and Russian research history do not by themselves establish FDA approval, safety, effectiveness, quality, or lawful human-use marketing.

## Sitemap

See the full [markdown sitemap](/sitemap.md) for all pages.